INK 128 (MLN0128) is primarily used in research and clinical studies targeting cancer treatment. It functions as a potent inhibitor of mTOR (mechanistic target of rapamycin), a critical protein involved in cell growth, proliferation, and survival. By blocking mTOR signaling pathways, INK 128 disrupts the growth of cancer cells, particularly in tumors that rely on this pathway for progression. It has shown promise in preclinical studies for treating various cancers, including breast, prostate, and pancreatic cancers. Additionally, it is being explored in combination therapies to enhance the effectiveness of other anticancer drugs. Its ability to inhibit both mTORC1 and mTORC2 complexes makes it a valuable tool in understanding and targeting cancer metabolism and resistance mechanisms.